EAEllen J. Anderson

Ellen J. Anderson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ellen J. Anderson has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Critical Review of Persistent Gastrointestinal and Extraintestinal Symptoms in Quiescent Inflammatory Bowel Disease: Time for Greater Precision and Clarity

    by Alexandra Mack, Emma P. Halmos, Tamara Mogilevski, Ellen J. Anderson, Kirstin M. Taylor, Rebecca P. Burgell, Peter R. Gibson

    Background and Aims: Despite improved therapies targeting inflammation in inflammatory bowel disease, persistent gastrointestinal and extraintestinal symptoms in those believed to be in remission are highly prevalent with significant impact on patient function and quality of life. This review aims to summarize the scale of the problem, to identify the limitations of previous studies, and to propose how these may be addressed. Methods: The published literature was extensively reviewed. Results: Persistent gastrointestinal symptoms are reported in up to 40% of patients with inflammatory bowel disease in apparent remission and have mostly been characterized using the Rome criteria, which are unvalidated in this population. They are also closely linked to anxiety/depression and fatigue. Importantly, studies have frequently failed to use tests with high negative predictive values to exclude intestinal inflammation and have assumed severe symptoms are inflammatory in nature. The presence of ongoing inflammation and different mechanisms underlying the development of symptom‐generating abnormalities, including visceral hypersensitivity and central sensitization, that are shared by disorders of gut–brain interaction are evident in the small number of studies performed. Thus, the concept that inflammatory and noninflammatory symptoms are mutually exclusive may be fallacious. Conclusions: Persistent gastrointestinal symptoms are common in patients with inflammatory bowel disease in apparent remission, but variable criteria to define inflammatory remission may introduce a high risk of bias within existing literature. Further research using objective and robust measures of inflammatory remission is key to better defining this population and to clarifying pathophysiological mechanisms so that effective management strategies can be developed.


  • Open Access

    Clinical Trial: The Effects of Emulsifiers in the Food Supply on Disease Activity in Crohn's Disease: An Exploratory Double‐Blinded Randomised Feeding Trial

    by Jessica A. Fitzpatrick, Peter R. Gibson, Kirstin M. Taylor, Ellen J. Anderson, Antony B. Friedman, Zaid S. Ardalan, Rebecca L. Smith, Emma P. Halmos

    Background: Advice to avoid dietary emulsifiers in Crohn's disease (CD) is based on preclinical data.Aims: To examine the effect of diets high (HED) and low (LED) in emulsifiers in the food supply on disease activity in CD.Methods: In a double‐blinded, randomised feeding study, we randomised adults with symptomatic, sonographically active CD with ileal involvement on ≥ 2 months' stable medical therapy to 4 weeks of a HED or LED modelled on Australian healthy eating guidelines. We measured the Harvey‐Bradshaw Index (HBI), sonographic indices (IBUS‐SAS, bowel wall thickness), quality of life (QOL) and fatigue at baseline and study completion.Results: We randomised 24 patients, mean age 37 (95% CI 32, 41) years, 12 male, HBI 6 (6, 8), bowel wall thickness 6.0 (5.5–6.6) mm. Adherence was > 95%. Clinical remission (HBI < 5) occurred in 9/12 on HED and 7/12 on LED; 2 and 3, respectively, withdrew early with increasing gastrointestinal symptoms. IBUS‐SAS fell from 51 (35, 68) to 33 (15, 51) on HED (p = 0.014) and from 57 (38, 76) to 44 (29, 59) on LED (p = 0.01). Bowel wall thickness reduced by 34% on HED and 15% on LED in those who completed the study. QOL and fatigue improved on both diets (p ≤ 0.05). There were no statistically significant differences in outcomes between diets.Conclusions: In the context of a healthy diet, the emulsifier content had no influence over disease activity over 4 weeks in patients with CD. Recommendations to avoid emulsifiers in patients with active CD are not supported.Australian New Zealand Clinical Trials Registry (ACTRN12619001099112).


  • Comparison of Digitally Delivered Gut-Directed Hypnotherapy Program With an Active Control for Irritable Bowel Syndrome

    by Ellen J. Anderson, Simone L. Peters, Peter R. Gibson, Emma P. Halmos

    INTRODUCTION: Gut-directed hypnotherapy (GDH) treats irritable bowel syndrome (IBS), but its accessibility is limited. This problem may be overcome by digital delivery. The aim of this study was to perform a randomized control trial comparing the efficacy of a digitally delivered program with and without GDH in IBS. METHODS: Adults with IBS were randomized to a 42-session daily digital program with the GDH Program (Nerva) or without (Active Control). Questionnaires were completed to assess gastrointestinal symptoms through IBS Symptom Severity Scale (IBS-SSS), quality of life, and psychological symptoms (Depression Anxiety and Stress Scale-21) at regular intervals during the program and 6 months following the conclusion on the intervention. The primary end point was the proportion of participants with ≥50-point decrease in IBS-SSS between the interventions at the end of the program. RESULTS: Of 240/244 randomized participants, 121 received GDH Program—the median age 38 (range 20–65) years, 90% female, IBS-SSS 321 (interquartile range 273–367)—and 119 Active Control—36 (21–65), 91% female, IBS-SSS 303 (255–360). At program completion, 81% met the primary end point with GDH Program vs 63% Active Control ( P = 0.002). IBS-SSS was median 208 (interquartile range 154–265) with GDH and 244 (190–308) with control ( P = 0.004), 30% reduction in pain was reported by 71% compared with 35% ( P < 0.001), and IBS quality of life improved by 14 (6–25) compared with 7 (1–15), respectively ( P < 0.001). Psychological status improved similarly in both groups. DISCUSSION: A digitally delivered GDH Program provided to patients with IBS was superior to the active control, with greater improvement in both gastrointestinal symptoms and quality of life and provides an equitable alternative to face-to-face behavioral strategies.